Texas’ ambitious bid to be a global cancer-research hub is running into the state’s own immigration politics. A Texas Tribune investigation published July 22 shows that Governor Greg Abbott’s January directive restricting public universities’ use of the H-1B visa now risks stalling hundreds of oncology projects at Houston’s MD Anderson Cancer Center—the nation’s top recipient of National Cancer Institute grants. Abbott forbade public institutions from filing new H-1B petitions without Texas Workforce Commission (TWC) approval until at least May 2027. Universities must prove no qualified Texans are available and may be barred from sponsoring nationals of so-called “prohibited” countries, including China. MD Anderson currently employs 277 H-1B researchers; across Texas’ 44 public higher-ed entities the tally tops 3,300. Immigration attorneys interviewed warned the order sends a “chilling message” to foreign post-docs already weighing Canada or the U.K. Research chiefs argue that more than 40 percent of U.S. biomedical graduate students are foreign-born and that visa bottlenecks will slow clinical trials and jeopardise the state’s US $3 billion bet on becoming a cancer-cure powerhouse. For corporate R&D mobility teams—not just in life sciences—the case underscores how state-level visa interventions can collide with federal policy, adding a new layer of risk when siting labs or forging university partnerships. Companies funding joint projects with Texas schools should review staffing timelines, consider J-1 or O-1 alternatives, and build relocation clauses into grant agreements should talent have to move out of state.
Source: The Texas Tribune
